Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th
Sight Sciences (NASDAQ: SGHT), an eyecare technology company specializing in innovative interventional technologies, has announced its participation in the Stifel 2025 Virtual Ophthalmology Forum. The company's management will deliver a presentation on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Investors and interested parties can access both the live and archived versions of the fireside chat through the Investors section of Sight Sciences' website at investors.sightsciences.com.
The company focuses on developing and commercializing technologies aimed at transforming care and enhancing patients' lives in the eyecare sector.Sight Sciences (NASDAQ: SGHT), un'azienda tecnologica nel settore dell'oftalmologia specializzata in tecnologie interventistiche innovative, ha annunciato la sua partecipazione al Stifel 2025 Virtual Ophthalmology Forum. Il management dell'azienda terrà una presentazione martedì 27 maggio 2025, alle 09:00 PT / 12:00 ET. Investitori e interessati potranno accedere sia alla diretta che alla versione registrata del dialogo informale tramite la sezione Investors del sito di Sight Sciences all'indirizzo investors.sightsciences.com.
L'azienda si concentra sullo sviluppo e la commercializzazione di tecnologie volte a trasformare l'assistenza e migliorare la vita dei pazienti nel settore dell'oftalmologia.
Sight Sciences (NASDAQ: SGHT), una empresa tecnológica especializada en tecnologías intervencionistas innovadoras para el cuidado ocular, ha anunciado su participación en el Stifel 2025 Virtual Ophthalmology Forum. La dirección de la compañía realizará una presentación el martes 27 de mayo de 2025, a las 09:00 am PT / 12:00 pm ET. Inversores y personas interesadas podrán acceder tanto a la transmisión en vivo como a la versión archivada de la charla a través de la sección Investors en el sitio web de Sight Sciences en investors.sightsciences.com.
La empresa se enfoca en desarrollar y comercializar tecnologías destinadas a transformar la atención y mejorar la vida de los pacientes en el sector del cuidado ocular.
Sight Sciences (NASDAQ: SGHT)는 혁신적인 개입 기술을 전문으로 하는 안과 기술 회사로, Stifel 2025 Virtual Ophthalmology Forum에 참여한다고 발표했습니다. 회사 경영진은 2025년 5월 27일 화요일 오전 9시 PT / 오후 12시 ET에 발표를 진행할 예정입니다. 투자자 및 관심 있는 분들은 Sight Sciences 웹사이트의 Investors 섹션 investors.sightsciences.com을 통해 라이브 및 녹화된 대화를 모두 시청할 수 있습니다.
이 회사는 안과 분야에서 치료 방식을 혁신하고 환자의 삶을 향상시키기 위한 기술 개발 및 상용화에 주력하고 있습니다.
Sight Sciences (NASDAQ: SGHT), une entreprise technologique spécialisée dans les technologies interventionnelles innovantes en ophtalmologie, a annoncé sa participation au Stifel 2025 Virtual Ophthalmology Forum. La direction de la société présentera une intervention le mardi 27 mai 2025 à 09h00 PT / 12h00 ET. Les investisseurs et les personnes intéressées peuvent accéder à la fois à la diffusion en direct et à la version enregistrée de la discussion via la section Investors du site web de Sight Sciences à l'adresse investors.sightsciences.com.
L'entreprise se concentre sur le développement et la commercialisation de technologies visant à transformer les soins et à améliorer la vie des patients dans le secteur de l'ophtalmologie.
Sight Sciences (NASDAQ: SGHT), ein Unternehmen für Augentechnologie, das sich auf innovative interventionelle Technologien spezialisiert hat, hat seine Teilnahme am Stifel 2025 Virtual Ophthalmology Forum angekündigt. Das Management des Unternehmens wird am Dienstag, den 27. Mai 2025, um 09:00 Uhr PT / 12:00 Uhr ET eine Präsentation halten. Investoren und Interessierte können sowohl die Live-Übertragung als auch die aufgezeichnete Version des Gesprächs über den Bereich Investors auf der Website von Sight Sciences unter investors.sightsciences.com abrufen.
Das Unternehmen konzentriert sich auf die Entwicklung und Vermarktung von Technologien, die die Versorgung revolutionieren und das Leben der Patienten im Bereich der Augenheilkunde verbessern sollen.
- None.
- None.
MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum.
Sight Sciences’ management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the Investors section of the Company’s website at https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2025 Sight Sciences. All rights reserved.
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com
FAQ
When is Sight Sciences (SGHT) presenting at the Stifel 2025 Virtual Ophthalmology Forum?
How can investors access Sight Sciences' (SGHT) presentation at the Stifel Ophthalmology Forum?
What is Sight Sciences' (SGHT) main business focus?
What type of event is Sight Sciences (SGHT) participating in?
